IRS Form 8947 Guide: Branded Prescription Drug Information

Introduction – What Is Form 8947?

IRS Form 8947, titled Report of Branded Prescription Drug Information, is an annual federal tax information report administered by the Internal Revenue Service (IRS) and the U.S. Department of the Treasury. It was created under Section 9008 of the Patient Protection and Affordable Care Act (ACA).

The form is used by pharmaceutical manufacturers and importers to report data about their branded prescription drugs sold to specified federal and state healthcare programs. The IRS uses this information to calculate each company’s share of an annual, industry-wide fee imposed on branded drug makers.

Purpose of the Form – Why Does Form 8947 Exist?

Under Section 9008 of the ACA, the federal government collects an annual statutory fee totaling billions of dollars from the pharmaceutical industry. Rather than charging a flat tax rate on profits, the law distributes this fixed annual amount among manufacturers and importers based on each company’s relative market share of branded drug sales to government programs.

Form 8947 provides the mechanism for pharmaceutical companies to provide the IRS with verified data before the fee is calculated. It allows covered entities to report their National Drug Codes (NDCs), claim exclusions for qualifying orphan drugs, document Medicaid state supplemental rebates, and establish controlled group structures. Without this form, the IRS calculates fees using unadjusted raw data from government agencies, often leading to significantly higher fee assessments.

Who Needs to File This Form?

You should file Form 8947 if your business qualifies as a “covered entity” under federal healthcare regulations. A covered entity is any manufacturer or importer that holds legal rights to a branded prescription drug and generates gross receipts from sales to specified government programs.

Filing is especially critical for companies that meet the following operational criteria:

• Substantial Government Sales: Your enterprise has gross receipts exceeding $5 million from sales of branded prescription drugs to programs such as Medicare Parts B and D, Medicaid, the Department of Veterans Affairs (VA), the Department of Defense (DoD), and TRICARE.
• Orphan Drug Manufacturers: You manufacture designated orphan drugs under Section 45C and want to exclude those sales from the annual fee calculation.
• Rebate Offsets: You paid Medicaid state supplemental rebates and want those rebates deducted from your gross sales figures.
• Corporate Controlled Groups: You are part of an affiliated corporate group that needs to appoint a single “designated entity” to handle fee correspondence and consolidated payment.

Who Is Exempt / Not Required to File?

Many participants in the healthcare supply chain are exempt from filing Form 8947. You are not required or expected to submit this form if:

• Generic and OTC Drug Makers: You exclusively manufacture or import generic pharmaceuticals or over-the-counter (OTC) medications that do not require a branded new drug application.
• Pure Commercial Sellers: Your branded prescription drug sales are made exclusively through private commercial insurance plans, with zero sales or reimbursements through Medicare, Medicaid, VA, DoD, or TRICARE.
• Wholesalers and Pharmacies: You operate as a distributor, retail pharmacy, or hospital that purchases and resells medications but does not hold the manufacturer labeler code or import rights.
• Micro-Volume Producers: Small biotech firms with branded drug sales to government programs totaling less than $5 million are subject to a zero percent fee rate, though filing may still be advisable to confirm designated entity status.

When to File Form 8947

Form 8947 is an annual information return with a strict submission schedule. The form is generally due on or before November 1 of the year preceding the fee year (or the next business day if November 1 falls on a weekend).

The annual fee calculation follows a multi-stage timeline:

• November 1: Covered entities submit Form 8947 with their sales, rebate, and orphan drug details.
• Late Spring (April–May): The IRS issues a preliminary fee calculation letter (Letter 4657) showing your tentative allocated fee.
• May 15: Deadline for covered entities to submit an error report or formal dispute regarding the preliminary fee.
• August 31: The IRS issues the final fee calculation letter (Letter 4658).
• September 30: Final payment of the annual branded prescription drug fee is due to the U.S. Treasury.

Where and How to File

Covered entities have two primary ways to file Form 8947:

• Electronic Filing: Form 8947 can be submitted electronically through the IRS ACA Form Acceptance system on the IRS website. Electronic submissions must be accompanied by a signed Form 8453-R (Declaration and Signature for Electronic Filing of Forms 8947 and 8963).
• Paper Filing: If filing on paper, send the completed form and schedules as a flat mailing (do not fold, staple, or tape the documents) to the designated IRS address as per instructions for Form 8947.

Step-by-Step Instructions to Fill Form 8947

Form 8947 consists of preliminary identification items followed by detailed schedules covering corporate affiliation, drug codes, and statutory exclusions.

Preliminary Items (Page 1)

Select your filing status under Item A (first-time filer, subsequent-year filer with changes, subsequent-year filer without changes, or reporting rebates only). Under Item B, indicate whether you are filing as a single covered entity or on behalf of a controlled group. Under Item C, enter the sales year being reported.

Part-by-Part Line Item Breakdown

Part Number	Form Focus	Key Instructions
Part I	Controlled Group Members	List every corporate member of the controlled group that manufactures or imports branded drugs, including legal names, addresses, and Employer Identification Numbers (EINs). Designate the primary entity responsible for payments.
Part II	Branded Prescription Drug Information	Report each 11-digit National Drug Code (NDC), proprietary and generic names, FDA approval dates, and any Medicaid state supplemental rebate amounts paid for that specific drug.
Part III	Section 45C Orphan Drug Information	List the NDCs of drugs designated as orphan drugs under Section 526 of the Federal Food, Drug, and Cosmetic Act for which an orphan drug tax credit was allowed under Section 45C.
Part IV	Signatures and Certification	An authorized corporate officer must sign and date the return under penalties of perjury, certifying that all statements and attached schedules are accurate.

Required Documents and Information Needed Before Filling

To prepare an accurate Form 8947, assemble the following commercial, regulatory, and tax records:

• FDA Drug Listings: Current FDA registration documents confirming all 11-digit National Drug Codes (NDCs) and labeler codes assigned to your company.
• Medicaid Supplemental Rebate Records: Certified accounting statements from state Medicaid agencies verifying the exact rebate amounts paid during the sales year.
• FDA Orphan Drug Designations: Official designation letters from the FDA Office of Orphan Products Development confirming rare disease designations.
• Form 8820 Records: Prior corporate tax returns showing allowable Section 45C Orphan Drug Credits claimed for the drug.
• Controlled Group Organizational Charts: Corporate structure diagrams showing ownership percentages among all affiliated domestic and foreign manufacturing entities.

Common Mistakes to Avoid

Omissions on Form 8947 can inflate your company’s federal fee assessment by millions of dollars. Watch out for these frequent mistakes:

• Missing the November 1 Deadline: If you fail to file Form 8947 on time, the IRS will calculate your fee based solely on raw government program sales data, completely ignoring your orphan drug exclusions and rebate offsets.
• Improper NDC Formatting: Entering National Drug Codes without the standard 11-digit configuration (including leading zeros) will cause electronic validation errors.
• Claiming Ineligible Orphan Drugs: Listing a drug under Part III that was subsequently approved by the FDA for a broad, non-rare disease indication. Once a drug is approved for a non-orphan indication, it loses its fee exclusion.
• Failing to Appoint a Designated Entity: Controlled groups that fail to clearly identify a single designated entity face administrative confusion, as the IRS may issue correspondence to multiple corporate subsidiaries.
• Folding Paper Submissions: Folding, stapling, or taping paper forms interferes with high-speed IRS optical scanners in Ogden, Utah, causing processing delays.

Penalties for Non-Filing or Errors

While Form 8947 does not impose an automatic late-filing monetary penalty, the indirect financial consequences of failing to file are severe:

• Artificially Inflated Annual Fee: The IRS will determine your company’s market share without factoring in statutory exclusions. Losing your orphan drug deductions or Medicaid rebate credits can dramatically increase your fee liability.
• Failure-to-Pay Penalties: Once the final fee is assessed on August 31, failing to pay by September 30 triggers mandatory late-payment penalties and compound daily interest under Section 6601.
• Joint and Several Liability: Under Section 9008, every member of a controlled group is jointly and severally liable for the entire fee assessed on the group.
• Non-Deductibility: The branded prescription drug fee is classified as an excise tax and is strictly non-deductible for federal income tax purposes under IRC Section 275.

Related Forms and Schedules

Form 8947 operates within a specialized group of ACA compliance documents and corporate tax forms:

• Form 8453-R: Declaration and Signature for Electronic Filing of Forms 8947 and 8963.
• Form 8963: Report of Health Insurance Provider Information (the companion ACA annual fee form for health insurance carriers).
• Form 8820: Orphan Drug Credit (used to establish tax credit history for Part III exclusions).
• Form 1120: U.S. Corporation Income Tax Return.

Frequently Asked Questions

What is the Branded Prescription Drug (BPD) fee?

The BPD fee is an annual, non-deductible fee collected by the federal government from pharmaceutical manufacturers and importers based on their share of branded drug sales to government healthcare programs.

Is submitting Form 8947 mandatory?

Submitting Form 8947 is technically voluntary, but practically essential. If you do not file, the IRS will still calculate and bill you for the fee using government sales data, but you will lose the opportunity to reduce that fee with orphan drug exclusions and Medicaid rebate offsets.

How does the orphan drug exclusion work on Form 8947?

Sales of a branded drug designated as an orphan drug under Section 526 of the Federal Food, Drug, and Cosmetic Act are excluded from the fee calculation, provided an orphan drug credit was allowed under Section 45C and the drug has not been approved for non-orphan indications.

What are “specified government programs”?

Under Section 9008, specified government programs include Medicare Part B, Medicare Part D, Medicaid, the Department of Veterans Affairs programs, Department of Defense programs, and TRICARE.

Can a company deduct the BPD fee as a business expense?

No. Federal tax law explicitly states that the annual branded prescription drug fee is an excise tax that cannot be deducted on corporate income tax returns (such as Form 1120).

What should we do if the IRS preliminary fee letter is inaccurate?

If you receive Letter 4657 and identify errors in sales figures, orphan drug treatment, or rebate credits, you must submit a formal written error report to the IRS no later than May 15.

Conclusion – Key Takeaways Summarized

IRS Form 8947 is a crucial compliance report for pharmaceutical manufacturers and importers participating in government healthcare programs. It directly impacts how much your company will be billed under the ACA Section 9008 annual branded prescription drug fee.

To avoid overpaying your annual fee assessment, gather your 11-digit NDCs early, verify Medicaid supplemental rebates, substantiate your Section 45C orphan drug exclusions, and ensure your completed Form 8947 is submitted by the November 1 deadline.